Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Condition:   Basal Cell Nevus Syndrome Intervention:   Drug: Patidegib Topical Gel, 2% Sponsor:   PellePharm, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 16, 2020 Category: Research Source Type: clinical trials

PellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
SAN FRANCISCO– December 2, 2019– PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 2, 2019 Category: Pharmaceuticals Source Type: clinical trials

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Condition:   Recurrent Basal Cell Carcinoma Interventions:   Drug: Patidegib Topical Gel, 2%;   Drug: Patidegib Topical Gel, Vehicle Sponsor:   PellePharm, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2019 Category: Research Source Type: clinical trials

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas (SEB) in Gorlin Syndrome Patients
Condition:   Basal Cell Nevus SyndromeInterventions:   Drug: patidegib;   Drug: vehicle gelSponsor:   PellePharm, Inc.Recruiting - verified May 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2016 Category: Research Source Type: clinical trials

Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas
Conditions:   Basal Cell Nevus Syndrome;   Gorlin's SyndromeInterventions:   Drug: GDC-0449;   Procedure: Aminolevulinic acid %20 topical solution + blue lightSponsors:   Children's Hospital & Research Center Oakland;   Children's Hospital & Research Center Oakland;   GenentechRecruiting - verified February 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 14, 2012 Category: Research Source Type: clinical trials

Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas
Conditions:   Basal Cell Nevus Syndrome;   Gorlin's SyndromeInterventions:   Drug: GDC-0449;   Procedure: Aminolevulinic acid %20 topical solution + blue lightSponsors:   Children's Hospital & Research Center Oakland;   Children's Hospital & Research Center Oakland;   GenentechActive, not recruiting - verified July 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 14, 2012 Category: Research Source Type: clinical trials

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Condition:   Basal Cell Carcinoma Interventions:   Drug: LDE225B;   Drug: Vehicle Sponsor:   Novartis Pharmaceuticals Terminated - verified February 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2010 Category: Research Source Type: clinical trials